Haen, Sebastian P. http://orcid.org/0000-0002-3655-4668
Löffler, Markus W. http://orcid.org/0000-0003-2513-1317
Rammensee, Hans-Georg
Brossart, Peter
Article History
Accepted: 5 May 2020
First Online: 22 June 2020
Competing interests
: S.P.H. has acted as an advisory board member for Abbvie, Bristol–Myers Squibb, MSD and Roche, and is a co-inventor of several patents owned by Immatics Biotechnologies. M.W.L. is a co-inventor of several patents owned by Immatics Biotechnologies, and has acted as a consultant and/or advisory board member for Boehringer Ingelheim. H.-G.R. has ownership interest (including shares) in CureVac, Immatics Biotechnologies and Synimmune, is a co-inventor and/or has shared interests in several patents held by CureVac, Immatics Biotechnologies and Synimmune, and is a co-inventor and shares the patent for the adjuvant candidate XS15. P.B. has acted as a consultant or advisory board member for Amgen, AstraZeneca, Bristol–Myers Squibb, MSD and Roche, has received speaker’s fees from Abbvie, AstraZeneca, Bristol-Myers Squibb, and MSD, and has ownership interests in Immatics Biotechnologies.
Free to read: This content has been made available to all.